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ABSTRACT 
 
The p38 mitogen-activated protein kinase [p38(MAPK)] mediates responses to 
extracellular stressors. An increase in the phosphorylated form of p38(MAPK) [p-
p38(MAPK)] has been associated with early events in Alzheimer disease (AD). Although 
most often associated with processes including apoptosis, inflammation and oxidative 
stress, p-p38(MAPK) also mediates beneficial physiological functions, such as cell 
growth, survival and phagocytosis of cellular pathogens. The presence of amyloid 
plaques [β-amyloid aggregates] is one of the hallmarks of AD-related pathology. As 
p38(MAPK) has been detected in the vicinity of amyloid plaques, we combined 
immunohistochemistry and stereological sampling to quantify the distribution of plaques 
and p-p38(MAPK)-immunoreactive (IR) cells in the sensorimotor cortex of 3-, 6- and 
10-month-old TgCRND8 mice. This animal model expresses an AD-related variant of 
the human amyloid-β protein precursor (APP). The aggressive nature of this variant was 
confirmed by the appearance of both dense-core (thioflavin-S-positive) and diffuse 
plaques, even in the youngest mice. p-p38(MAPK)-IR cells were associated with both 
dense-core and diffuse plaques, but the age-dependent increase in the density of plaque-
associated p-p38(MAPK)-IR cells was limited to dense-core plaques. Furthermore, the 
density of these dense-core plaque-associated cells was inversely correlated with the size 
of the core within the given plaque, which suggests a role for these microglia in 
restricting core growth. Parenchymal p-p38(MAPK)-IR cells were also observed in both 
wildtype and TgCRND8 mouse cortex. However, the density of these parenchymal cells 
remained constant, regardless of age or genotype. The majority of p-p38(MAPK)-IR 
cells were predominantly co-immunoreactive for the Macrophage-1 (CD11b) microglial 
marker, regardless of whether they were associated with plaques or localized to the 
parenchyma. This constitutive presence of p-p38(MAPK)-IR microglia in aging mouse 
brain is suggestive of a longitudinal role for this kinase in normal brain physiology. The 
plaque-associated pool of p-p38(MAPK)-IR microglia appears to restrict -amyloid core 
development. This, as well as the non-pathological role of p-p38(MAPK) in parenchyma, 
needs to be considered when interpreting p38(MAPK)-dependent mechanisms in the 
context of both experimental and clinical AD. 
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1. INTRODUCTION 
1.1 Alzheimer’s disease (AD) 
1.1.1 Definition and classification of AD 
 Alzheimer’s disease (AD) is the most common form of dementia [1]. This 
progressive, neurodegenerative and incurable disease was first described by the German 
psychiatrist Alois Alzheimer in 1906, and then was named after him [2]. Currently, AD 
is one of the most prevalent diseases related to aging [3]. In 2006, there were 26.6 
million sufferers worldwide [4]. AD includes sporadic [late-onset] and early-onset forms 
of the disease. The sporadic form of AD is the most common and accounts for almost 
90% of diagnosed cases [5]. The rate of incidence of AD is approximately 5% of people 
65 years old and this rate doubles every 5 years thereafter [3, 5]. Almost 50% of people 
aged 85 years or older are affected by AD [5]. In contrast, cases of early-onset AD are 
usually those diagnosed before the age of 65 years. It is the less prevalent form of AD, 
accounting for only 5-10% of all cases [4]. Furthermore, approximately half of the cases 
of early-onset AD are familial AD (FAD), which implicates a genetic predisposition [6]. 
Three predisposition genes include those coding for the proteins presenilin-1 (PS1), 
presenilin-2 (PS2), and amyloid- protein precursor (APP) [7].  
 
1.1.2 Characteristics of AD 
 Although the course of AD is unique for every individual, there are still many 
common symptoms. Generally, based on the extent of progressive cognitive and 
functional impairment, the disease can be divided into four stages, with an increasing 
degree of dementia: (a) pre-dementia, (b) early, (c) moderate, and (d) advanced [8, 9]. 
The cognitive and behavioral changes associated with the first stage are most often 
mistaken as changes relating to aging or stress [10]. The most complex of daily living 
activities can be affected in this very early stage and memory loss can be determined 
using the appropriate neuropsychological testing [9, 11]. Further impairment of thinking 
and memory shows up during the second stage of AD. In a small portion of the patients, 
difficulties with language, perception and execution of movements are more prominent 
than memory problems [8]. At the third (or moderate) stage, a person with AD is unable 
to perform the most common activities of daily living. Speaking and writing skills are 
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progressively lost. At the same time, memory problems further worsen and long-term 
memory becomes impaired [8, 12]. During the fourth (or advanced) stage, patients are 
completely dependent on caregivers. The ability to speak is completely lost and muscle 
mass and mobility deteriorate; at this stage, patients are bedridden and lose the ability to 
feed themselves. Although AD cannot itself directly cause the death of people, it is 
considered a terminal illness as it predisposes to external factors that facilitate infections 
such as pneumonia and pressure ulcers, which ultimately precipitate death [8, 13]. 
 
1.1.3 Pathology of AD 
 The neuropathological changes of AD include neuronal degeneration, the 
presence of intracellular neurofibrillary tangles (NFT) and formation of extracellular 
amyloid (senile) plaques (Figure 1) [1]. 
 Currently, the ‘tau’ and the ‘beta-amyloid’ hypotheses are the most popular 
theories used to explain AD [14]. The ‘tau’ hypothesis proposes that 
hyperphosphorylation of the microtubule-associated protein tau causes it to dissociate 
from the cytoskeleton and aggregate with other threads of tau to form paired helical 
filaments (PHFs), which eventually form the intracellular NFTs [15].When this occurs, 
intracellular transport is compromised, resulting in the malfunction of biochemical 
communication between neurons. The death of the cell is then imminent [16]. 
 The ‘beta-amyloid’ hypothesis proposes that the amyloid plaques are the 
fundamental cause of the disease [17]. The beta-amyloid (Aβ) toxic peptide is the major 
constituent of the amyloid plaque and these plaques/aggregates are often most evident in 
limbic and association cortices of the AD brains [1, 14]. Elevated levels of Aβ then 
induce microglial activation and proliferation, and promote the release of 
proinflammatory cytokines, such as interleukins (IL) and tumor necrosis factors (TNF) 
[14]. 
 
1.1.4 The Amyloid Protein Precursor 
 The Aβ peptide contains 39 to 43 amino acids and is generated following the 
cleavage of the amyloid precursor protein (APP) molecule [18]. The APP gene is located 
on chromosome  21 and the  APP protein  is an integral transmembrane protein expressed  
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in many tissues and concentrated in the synapses of neurons [19, 20]. APP can be 
processed by three enzymes, e.g. -, - and -secretases [21]. Under normal conditions, 
APP is cleaved by α-secretase between residues 16 and 17 within the A peptide region 
to release sAPP[22] (Figure 2). Under certain conditions, successive action of the - 
and -secretases generates the A peptide (note that cleavage by -secretase, given that it 
cleaves the APP protein within the A sequence, precludes generation of the intact A 
peptide). The AD-related mutations in APP, which are often near the β-secretase site, 
promote cleavage by β-secretase and thus alter the availability of Aβ. β-secretase cleaves 
APP between residues 596 and 597, thus shedding the N-terminus of APP and leaving 
the C-terminus of APP (C99; because of the number of residues it contains) [23]. The 
membrane-bound C99 can then be cleaved by γ-secretase to generate Aβ peptides of 
varying length (e.g. 39-43 amino acids) [24] (Figure 2). The most common forms of Aβ 
are Aβ40 and Aβ42. The Aβ42 peptide is more fibrillogenic and because of its tendency to 
aggregate into plaques, it has been historically associated with AD. In transgenic 
animals, the APP mutations associated with AD decrease the production of A40 or 
increase the production of Aβ42 [25], both of which leads to peptide aggregation and 
plaque formation. 
 
1.1.5 Classification of amyloid plaques 
The accumulation of the toxic Apeptide plays a central role in AD-related 
pathology and amyloid plaque formation [26]. Amyloid plaques are variable in both 
shape and size in the AD brains and individual tissue sections, but the average size is 
around 50 m [27]. Two types of plaques, designated as (a) ‘dense-core’ or (b) ‘diffuse’, 
are detected during amyloid deposition [14]. ‘Dense-core’ plaques are formed by the 
fibrillar/β-sheet conformation of Aβ and usually contain a central amyloid core. Much of 
the fibrillar Aβ found in the ‘dense-core’ plaques is Aβ42, since this longer and more 
hydrophobic form is prone to aggregation. However, the other species, Aβ40, can be also 
co-detected with Aβ42 in this kind of plaque [28]. The diameter of ‘dense-core’ plaque in 
brain sections varies widely from 10 to >120 m and the density of Aβ fibrils within the 
core (i.e. how compact they are) also shows great variability between plaques [14].  
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Currently, the time required to develop ‘dense-core’ plaques in humans is unknown, 
although it is assumed that months or years are needed for the gradual development of 
these lesions [28]. Moreover, the ‘dense-core’ plaques are associated with degenerative 
neural structures and an abundance of microglia and astrocytes. These microglia usually 
surround the outside of the plaque and their processes sometimes extend into the amyloid 
core [26]. The other kind of plaque is defined as ‘diffuse’ [30]. ‘Diffuse’ plaques are 
predominantly comprised of the Aβ42 peptide, with no or little Aβ40 immunoreactivity, 
and differ from ‘dense-core’ plaques that are formed by a mixture of Aβ42 and Aβ40 [31]. 
Furthermore, Aβ deposits in the ‘diffuse’ plaques lack the fibrillar and compressed 
conformation that is characteristic of the Aβ deposits in the ‘dense-core’ plaques; it is the 
absence of a clearly defined fibrillar and compacted center core that led to the ‘diffuse’ 
label for this category of plaques. In addition, there is very little or no detectable neural 
degeneration in or around most of these ‘diffuse’ plaques [32, 33]. These observations 
suggest that the ‘diffuse’ plaque is quite distinct from the ‘dense-core’ plaque in the AD 
brain [34]. However, another competing hypothesis proposes that ‘diffuse’ plaques 
represent immature lesions, which are the precursors to the ‘dense-core’ plaques. This 
hypothesis is supported by the evidence that in the same regions of AD patients, there is a 
mixture of ‘diffuse’ and ‘dense-core’ plaques, and ‘diffuse’ plaques develop before the 
fibrillar ‘dense-core’ plaques in transgenic mice expressing mutated human APP [14, 34]. 
 
1.1.6 AD-related animal models 
The use of animal models of AD is essential to the research of pathology and to the 
validation of preclinical and therapeutic approaches [35]. The following is a brief 
description of certain of these models. The Aβ peptide and tau protein are the major 
constituent of amyloid plaques and NFTs, respectively [1] and have been used to generate 
mouse models of AD. The Tg2576 mouse was the first APP transgenic model and it 
expressed APP containing the Swedish mutation (K670N/M671L) [the KM residues are 
immediately upstream of the A peptide fragment in APP; see Figure 2]. In the brains of 
this mouse model, transgenic APP was 5.6 times more than endogenous APP, and 
compared to wildtype littermates, a 5-fold increase in Aβ40 and 14-fold increase in Aβ42 
were observed [36]. TgCRND8 is another commonly used APP transgenic mouse model 
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that overexpresses both the Swedish (as above) and the Indiana (V717F) mutations. This 
dual substitution is very aggressive and results in elevated amounts of Aβ and the 
aggregation of Aβ into plaques at a very early age [37, 38]. Another useful model is the 
PS-1(M146V) mouse which overexpresses an AD-related PS-1 variant [39]. PS-1 is 
known as the central catalytic component of the γ-secretase complex and mutations in 
PS-1 not only cause the increased amount of Aβ42, but are also linked to early-onset 
familial AD [40, 41]. Recently, mice carrying mutated form of APP as well as PS-1, in 
addition to mutated tau-related genes, have been made available, e.g. the 
APPSW/TAUP301L/PS-1M146V mouse model. In this ‘triple transgene’ mouse model, Aβ 
and tau expression are doubled, and both amyloid plaques and NFTs are developed at an 
early age [42]. 
 
1.2 Mitogen-activated Protein Kinases (MAPKs) 
1.2.1 Brief overview of MAPKs 
Protein kinases transfer phosphate groups to the specific proteins as a means of 
regulating the function of these proteins [43]. Among the large group of protein kinases, 
the family of MAPK is well characterized. In specific substrates, it is serines and 
threonines that are the preferred amino acids targeted for phosphorylation by MAPKs 
[44]. Activation of MAPKs occurs via a series of ‘upstream’ events that is termed the 
‘MAPK cascade’. Each cascade consists of three levels of activation, with each level 
being represented by a specific kinase; MAPK, MAPK kinase (MKK, MEK) and MKK 
kinase (MKKK). A MKKK that is activated by extracellular stimuli phosphorylates a 
MKK on its serine and threonine residues; in turn this MKK activates a MAPK by 
phosphorylating specific threonine and tyrosine residues [45]. The specificity of the 
phosphorylation of MAPKs is based on the ‘TXY’ (T=threonine; X=any amino acid; 
Y=tyrosine) motifs found in the different MAPKs (Figure 3). The phosphorylation of 
both threonine and tyrosine residues in a given MAPK is required for full activation of 
MAPKs and [partial/full] inactivation will occur if either residue is dephosphorylated by 
a phosphatase [46]. The MAPK cascade is a highly conserved signal transduction 
pathway from yeast to mammalian cells [47]. It responds to many different external 
stimuli, which induce specific MAPK cascades to phosphorylate particular downstream 
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kinases from MKKK, MKK to MAPK and its substrates [48]. The various biological 
functions are determined by the diverse and specific cells, and as such MAPK cascades 
are involved in a wide range of cellular activities, including cell growth, differentiation, 
migration, survival, inflammation and apoptosis [45]. 
 
1.2.2 MAPKs subfamilies 
Three main subgroups of the MAPK family are well characterized: extracellular 
signal-regulated kinases (ERKs), c-Jun NH2-terminal kinases (JNK) and p38(MAPK) 
[49]. Sequence comparison reveals all the members in MAPK subfamilies share 40-45% 
amino acid identity, and the ‘TXY’ motifs targeted for phosphorylation by specific 
upstream MKKs in the three subfamilies are ‘TEY’ (single-letter code for threonine, 
glutamic acid, tyrosine) in ERKs, ‘TPY’ (threonine, proline, tyrosine) in JNKs, and 
‘TGY’ (threonine, glycine, tyrosine) in p38(MAPK). These motifs are located in a loop 
structure of the respective MAPKs close to the active site [50, 51]. 
ERK1 and ERK2 were the first cloned MAPKs [52]. Many different stimuli (e.g. 
growth factors, cytokines, ligands for heterotrimeric G protein-coupled receptors and 
viral infection) can activate the ERK pathway. In the typical ERK/MAPK cascade, 
MKKK is phosphorylated by small G protein Ras, and the MKK1/2 and ERK1/2 are then 
activated subsequently [51, 52]. Classically, the ERK pathway is involved in the control 
of cell proliferation, differentiation and mitosis [53]. In addition to ERK1/2, ERK3/4/5/7 
and 8 have been cloned recently and are associated with diverse biological functions [54]. 
Both JNK and p38(MAPK) cascade are activated by environmental stressors, 
such as UV radiation, X-rays, heat shock, osmotic shock as well as inflammation induced 
by cytokines, including interleukin-1 (IL-1) and tumor necrosis factor (TNF). Three 
members, JNK1, JNK2 and JNK3, are included in the JNKs subfamily [55]. In the JNK 
signaling pathway, although the activation of MKKKs is too complicated to be properly 
characterized (because of a diversity of various upstream stimuli), the activation of JNKs 
by MKK4 and MKK7 is well understood [55, 56]. Because this thesis is focused on 
p38(MAPK), this signaling pathway will now be examined in more detail. 
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1.2.3 Brief overview of p38(MAPK) signaling 
p38(MAPK) is the most recently identified, but also the most studied, MAPK of 
the three main MAPK subfamilies [58]. It was originally identified as a 38-kDa kinase 
rapidly phosphorylated in response to endotoxic lipopolysaccharide [59]. Four isoforms 
of p38(MAPK) have been reported and labeled as , ,  and . All four p38(MAPK) 
homologues share approximately 60-75% identity in their amino acid sequence, yet each 
isoform has its unique distribution, expression, activation and substrate affinity, all of 
which results in their varied functions [60-62].  
 
1.2.4 Localization of p38(MAPK) 
Among the four isoforms of p38(MAPK), p38(MAPK)-and genes are broadly 
expressed. p38(MAPK)- was the first identified and it is expressed ubiquitously. A high 
level of expression of p38(MAPK)- has been observed in the brain and heart [60, 63]. 
p38(MAPK)- and - are expressed in different tissues: p38(MAPK)- is mainly 
expressed in skeletal muscle, while p38(MAPK)-is more in peripheral organs, such as 
lung, kidney, testis, pancreas, ovary, adrenal and pituitary gland [64, 65]. All of the 
p38(MAPK) isoforms can be detected in both nucleus and cytoplasm as studies have 
demonstrated that when cells respond to external stimuli, p38(MAPK) can translocate 
from cytoplasm to the nucleus. However, some p38(MAPK) are able to activate specific 
cytoplasmic substrates and do not require a nuclear translocation event [66, 67]. 
 
1.2.5 The p38(MAPK) pathway 
The extracellular stimulation of the p38(MAPK) pathway is similar to that 
described above for JNKs [55]. Studies have demonstrated that inflammatory cytokines, 
such as IL-1, TNF, and G-protein-coupled receptor agonists are all able to trigger 
p38(MAPK)-mediated phosphorylation events [48]. In addition, many growth factors, 
including nerve growth factor (NGFs), insulin-like growth factor (IGFs) and transforming 
growth factor (TGFs) can activate p38(MAPK) [68] and environmental stressors, such as 
UV radiation, X-rays, heat shock and osmotic shock have also been implicated in its 
activation [55]. However, the various stimuli induce different upstream kinases to be 
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phosphorylated in diverse cell types, and the different isoforms of p38(MAPK) can then 
be activated by the various phosphorylated upstream kinases [48]. After the extracellular 
stimulation, low molecular weight GTP-binding protein, such as Rho family, Rac and 
Cdc42 as well as G-protein-coupled receptors all contribute to the upstream activation of 
MKKKs. The activated MKKKs then trigger the phosphorylation of the downstream 
MKK and the specific MAPK [69].  
The high-affinity MKK3/6 and low-affinity MKK4 are involved in p38(MAPK) 
activation [70]. MKK6 has been found to activate all four p38(MAPK) isoforms, whereas 
MKK3, which is 80% homologous to MKK6, cannot effectively phosphorylate 
p38(MAPK)-, but can phosphorylate p38(MAPK)-, - and -[71]. MKK4 has been 
implicated in the activation of p38(MAPK)-[70]. Thus, diverse stimulation and 
different upstream kinases lead to isoform-specific p38(MAPK) phosphorylation, and this 
will further cause several distinct p38(MAPK) substrates to be activated (Figure 3) [48]. 
 
1.2.6 Substrates of p38(MAPK) 
Inhibition of p38(MAPK) using pharmacological approaches or conditional 
knock-out animals allows for the identification of the physiological substrates for 
p38(MAPK). There are many substrates in both the nucleus and cytoplasm, suggesting 
multiple physiological effects can be induced based on subtle actions and interactions 
centered on the molecules involved in p38(MAPK) pathways [48]. The first kind of 
substrates are the protein kinases phosphorylated by activated p38(MAPK), termed 
MAPK-activated protein kinases (MAPKAPKs). The mitogen-activated kinases (MAKs) 
and stress-activated kinases (MSKs), MAPK-interacting kinases (MNKs) and 
MAPKAPK2, 3 and 5 all belong to the MAPKAPKs family, and depending on the signal 
from the upstream cascade, these MAPKAPKs can phosphorylate many other molecules 
to trigger diverse cellular responses [72]. The second category of p38(MAPK) substrates 
includes a number of important transcription factors, such as activating transcription 
factor (ATF)1, 2 and 6, SRF accessory protein 1 (Sap1), growth arrest and DNA damage 
inducible gene 153 (GADD153), p53, C/EBP-β, monocyte enhance factor 2A/2C 
(MEF2A/2C), MITF1, DDIT3, ELK1, NFAT, E1K-1, NFκB, Ets-1 and high mobility 
group-box protein 1 [50, 72, 73]. In addition, other types of substrates, such as Cpla2, 
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Na+-H+ exchanger isoforms-1 (NHE-1), tau, kertin 8, stathmin and the hyperpolarization-
activated cyclic nucleotide-gated channel have also been identified [74]. Moreover, 
proteins such as tyrosine hydroxylase, cAMP response element-binding protein (CREB), 
heat shock protein 27 (HSP27) and tritetraproline can also be activated indirectly by 
p38(MAPK) (Figure 4) [50, 74, 75]. Based on the great number of substrates, the 
p38(MAPK) cascade may be associated with multiple biological functions as diverse as 
inflammation, oxidative stress, apoptosis, cytokine production, cell growth, proliferation, 
differentiation, survival, regulation of gene expression at transcriptional level and 
cytoskeletal reorganization [48]. 
 
1.2.7 The physiological and pathological role of p38(MAPK) 
1.2.7.1 p38(MAPK) and inflammation 
The p38(MAPK)- isoform is expressed in many cell lines involved in 
inflammation and is primarily responsible for regulating proinflammatory responses [76]. 
Once  p38(MAPK) is  phosphorylated  [p-p38(MAPK)],  its  downstream  substrates  can 
induce inflammatory cytokines, such as IL, TNF and cyclooxygenase (COX) [69]. For 
example, the capacity of IL-1-induced IL-6 production and activation of MAPKAP-K2 
are reduced in embryonic stem cells taken from the p38(MAPK)- null mice when 
exposed to chemical stress [77]. More importantly, levels of IL-6 and TNF are also 
decreased in MAPKAP-K2-deficient mice [78]. Therefore, the p38(MAPK)/MAPKAP-
K2 pathway is crucial for inflammatory cytokine signaling and production [69]. The loss 
of expression of the inflammatory cytokines is thought to be mediated via mechanisms 
involving transcription and translation that are regulated by the p38(MAPK) pathway 
[69]. The transcription and translation of IL-1 and TNF mRNA are controlled by proteins 
called AU-binding proteins. These proteins always occupy the AU-rich regions in the 3′-
untranslated region, which can be found in IL-1 and TNF mRNA [79]. Normally, 
translation and transcription are blocked by the AU-binding protein and subsequently 
suppress the synthesis of IL-1 and TNF [80, 81]. However, when AU- binding proteins 
are phosphorylated by the p38(MAPK)/MAPKAP-K2, they can be released from the 
binding site of AU-rich regions in the RNAs. Therefore, once the AU-binding proteins 
are  phosphorylated  either  directly by  p38(MAPK) or  indirectly by  MAPKAP-K2,  the 
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inflammatory cytokines, IL-1 and TNF, are induced and secreted [80, 81, 83]. 
 
1.2.7.2 p38(MAPK) and cellular differentiation 
p38(MAPK) plays a critical role in cellular differentiation, with myogenic 
differentiation being the best characterized. An increasing number of muscle-specific 
genes are expressed during the process of myoblast conversions to differentiated 
myotubes in vivo, and this process can be observed in cell culture. In these cell lines, the 
persistent activation of p38(MAPK) results in the enhanced expression of related genes, 
which accelerates the formation of myotubes [84, 85]. However, if the cells are treated 
with p38(MAPK) inhibitors, both myogenic progression and the expression of muscle-
specific genes are blocked [86]. In another context, p38(MAPK) has been associated with 
enhancing neuronal differentiation via ‘crosstalk’ with other factors and kinases. The rat 
preneuronal pheochromocytoma PC12 cell line is well-characterized for the study of 
differentiation [87]. Using Nerve Growth Factor (NGF) to stimulate the cells and activate 
the MAPK pathways, both p38(MAPK) and ERK are activated, and cells stop 
multiplying and start to extend branching processes [88]. This effect can be explained as 
the ‘crosstalk’ (def.: in cell signaling, the term ‘crosstalk’ refers to the mechanism by 
which a condition can activate multiple responses and/or a ‘signal’ can be shared between 
different signalling pathways); crosstalk causes ERK and p38(MAPK) pathways to be 
activated by the same upstream kinase MKK following NGF stimulation [89]. Later on 
both the ERK and p38(MAPK) phosphorylate the transcription factor CREB, which can 
determine NGF-induced cell fate. Under the regulation of CREB, PC12 cells cease 
proliferation and begin differentiation [90]. 
 
1.2.7.3 p38 and cell migration 
By using a pharmacological p38(MAPK) inhibitor, another physiological role of 
p38(MAPK) in cell migration has been revealed. In a corneal wound healing model, two 
paracrine growth factors, e.g. hepatocyte growth factor and keratinocyte growth factor, 
induced the activation of p38(MAPK) pathway and a concurrent nuclear accumulation of 
phosphorylated p38(MAPK) in corneal epithelial cells. Treatment with the p38(MAPK) 
inhibitor SB203580 eliminates the activation and nuclear accumulation of p38(MAPK), 
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and the migration of epithelial cells is also blocked [91, 92]. The mechanism is thought to 
rely on the activation of the p38(MAPK) pathway associated with the expression of 
integrin, which leads to the epithelial-mesenchymal transition. In this case, p38(MAPK) 
may also regulate cell adhesion via the expression of paxillin, which is essential for cell 
migration [93-95]. In addition to numerous growth factors, cell migration also depends on 
cytoskeleton reorganization by the p38(MAPK) pathway. Indeed, inhibition of the 
p38(MAPK)/MAPKAPK2 pathway prevents cell migration by interrupting cytoskeleton 
polymerization [96]. 
 
1.2.7.4 p38(MAPK) in apoptosis and cell survival 
The cellular responses to p38(MAPK) signalling are diverse and complicated. The 
activation of p38(MAPK) cascades has been shown to promote cell death, whereas, under 
different condition, this cascade is also known to paradoxically enhance cell survival [97, 
98]. In CD4+T cells, the p38(MAPK) pathway is initiated by T cell receptor (TCR) 
ligation [99] and activation of the upstream kinases MKK3/6. MKK3 and MKK6 mediate 
T cell apoptosis, presumably through the phosphorylation of p38(MAPK) [100]. This 
hypothesis has been supported by the anti-CD3 mouse antibody-induced T cell apoptosis. 
The apoptosis can be blocked by treatment with the p38(MAPK) inhibitor SB203508 
[101]. However, p38(MAPK) signalling may also help to prevent apoptosis. Studies 
reported that the apoptosis of activated macrophages is induced, while the amino-terminal 
extension of MKK3 and MKK6 are cleaved by the bacterium bacillus anthracis 
generated lethal factor. However, once the cells persistently express the cleavage form of 
MKK3 and MKK6, they are no longer vulnerable to the bacterium bacillus anthracis-
induced apoptosis [99, 102]. Studies even revealed the duration of p38(MAPK) activation 
can determine whether induction or prevention of apoptosis occurs. In TNF-induced 
apoptosis, the activation of p38(MAPK) and JNK activation are divided into two phases. 
In the first phase, early activation of p38(MAPK) and JNK support the cell survival, 
whereas the activation of p38(MAPK) and JNK in the later phase is related to caspase-
dependent apoptosis [103, 104]. Thus, p38(MAPK) signalling can determine both cell 
apoptosis and survival, but the ultimate outcome depends on the context as well as on the 
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combination of the specific extracellular stimuli,  the upstream kinases involved and the 
duration of activation. 
Three pathologies in which p38(MAPK) has been implicated, namely cancer, 
cardiovascular dysfunction and Alzheimer/s disease (AD), will now be examined. 
 
1.2.7.5 p38(MAPK) in cancer and cardiovascular dysfunction 
One new role of p38(MAPK) that has been observed in recent years is its 
participation in cancer and tumor development. Inhibition of the p38(MAPK) cascade 
induces tumour development and metastasis. In contrast, overexpression of p38(MAPK) 
prevents tumourigenesis [82, 105], potentially through its role in cell proliferation and in 
regulating cell cycle at G0, G1/S and G2/M transitions [106]. Meanwhile, p38(MAPK) 
pathway also mediates DNA damage checkpoints function, which is a mechanism to 
monitor the cell division. In addition, the p38(MAPK) cascade can also promote or 
inhibit, in a context-dependent manner, the activation of several oncogenes [107, 108]. 
p38(MAPK) is being considered as a potential target in cancer and tumour therapies 
[109]. 
Two causes of cardiovascular dysfunction are (a) hypertension-induced pressure 
overload cardiac hypertrophy and (b) ischemic injury induced cardiomyocyte apoptosis 
and necrosis [82, 110]. The p38(MAPK) upstream kinases MKK3 and MKK6 were 
overexpressed in cardiomyocytes, which caused significant increase of hypertrophy 
responses. This result suggests that p38(MAPK) mediates to the cardiac hypertrophy 
[110, 111]. During ischemia in perfused heart, the p38(MAPK) cascade can be activated 
by the reactive oxygen species generated from the mitochondria. Inhibition of 
p38(MAPK) activity protects apoptosis and necrosis induced by hypoxia and can prevent 
cell death during ischemia reperfusion [112, 113]. 
 
1.2.7.6 The role of p38(MAPK) in AD  
p38(MAPK), particularly the phosphorylated form of p38(MAPK), is often 
expressed in vulnerable regions of AD brain, such as cortex and hippocampus [114, 115]. 
Moreover, p38(MAPK) has been suggested to contribute to the formation of the 
hyperphosphorylated tau (neurofibrillary tangles; NFTs) and amyloid plaques, as well as 
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other AD-related proteins [116-118]. In AD, more than thirty serine-threonine residues 
are phosphorylated and almost a half of the phosphorylated sites in tau are serine-
threonine residues [82]. Therefore, it is reasonable to suppose that the kinases of the 
MAPK family play a crucial role in tau phosphorylation [117, 119]. In recent years, 
through the use of [32P]-labeled ATP and phospho-specific antibodies, a number of 
p38(MAPK) phosphorylated residues in tau have been identified. Moreover, it has been 
demonstrated that tau is a stable substrate for p38(MAPK), especially for its 
p38(MAPK)-δ and -γ isoforms [120]. The phosphorylation of tau by p38(MAPK) results 
in the inability of tau to properly control microtubule assembly. Additionally, 
overexpression of p38(MAPK) in neuronal cells promotes tau phosphorylation and 
dissociation of tau  from the cytoskeleton to ultimately promote NFT formation. Thus, 
p38(MAPK) regulates the hyperphosphorylation of tau in response to cellular stress [120, 
121]. 
p38(MAPK) may influence AD progression by regulating other AD candidate 
protein activities, such as monoamine oxidase A (MAO-A) [116]. MAO-A is an 
important enzyme involved in the degradation of neurotransmitters, such as serotonin, 
dopamine and norepinephrine, and generates H2O2 as a reaction by-product [122]. Its role 
in modulating neurotransmitter availability makes MAO-A a major player in the 
neurobiology of depression. In addition to depression, MAO-A also plays a significant 
role in aging and age-related cognitive and mood disorders, such as learning, memory, 
cognition and sleep regulation. Interestingly, a link between a lifetime history of major 
depression and AD has been observed [123, 124]. Depressed patients have more amyloid 
plaques and NFTs in hippocampus and also people with major depression tend to be more 
likely to have a rapid decline into AD [125]. If MAO-A is contributing to depression in 
these patients, then this suggests that MAO-A might play a key role in the early 
neurochemical changes occurring in AD. Recently, an association between p38(MAPK) 
and MAO-A was proposed. Indeed, the inhibition of p38(MAPK) promotes MAO-A 
activity and MAO-A-sensitive toxicity in neuronal cell lines, which causes cell death. 
This may be induced by MAO-A-dependent oxidative stress and inflammation. However, 
overexpression of phosphorylated p38(MAPK) results in a decrease in MAO-A activity. 
As such, the regulation of MAO-A activity by p38(MAPK) could reduce MAO-A- 
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induced oxidative stress and inflammation in the early stages of AD [116]. 
A role for p38(MAPK) in AD has also been associated with amyloid plaque 
formation and development [118]. As mentioned before, the major amyloid plaque 
component Aβ induces microglial activation and causes the elevation in levels of pro-
inflammatory cytokines [14]. Meanwhile, one of the biological functions of p38(MAPK) 
is regulating the biosynthesis and expression of the pro-inflammatory cytokines [69, 76]. 
Therefore, both Aβ and p38(MAPK) are believed to contribute to the amyloid plaque 
formation and development [126]. In the cortex and hippocampus of AD-related 
amyloidosis animal models, phosphorylated p38(MAPK)-immunoreactive microglia and 
astrocytes can be observed in the vicinity of amyloid plaques [127, 128]. This 
phenomenon is thought to result from the presence of Aβ within the plaques and its 
ability to stimulate the nearby microglia and astrocytes, or even neurons; these cells then 
induce an elevated level of inflammatory cytokines in a p38(MAPK)-dependent manner. 
Ultimately, the inflammation may play a role in exacerbating the pathology of AD [114]. 
 
1.3 Project hypothesis 
The enzyme p38(MAPK) is a critical candidate protein in the cellular responses 
observed during AD; these involve inflammation and oxidative stress. It is because of its 
association with such responses that p38(MAPK) is most often thought of as being 
harmful. However, although p38(MAPK) has always been associated with apoptosis in 
vitro, its role in neuronal apoptosis in vivo remains ambiguous. Indeed, p38(MAPK) is 
constitutively activated in the cortex, hippocampus and cerebellum in normal conditions, 
and p38(MAPK) signaling has been shown to enhance cell growth, differentiation, 
survival [99, 129-132]. Moreover, p38(MAPK) activation has been observed in early 
stages of AD, when markers of apoptosis are uncharacteristically absent [133]. In the 
TgCRND8 mouse model of AD-related amyloidosis, amyloid plaque-associated cells that 
are immunoreactive for activated stress-associated protein kinases, e.g. JNK and the 
phosphorylated form of p38(MAPK) [p-p38(MAPK)], have been observed in the 
neocortex and hippocampus [114, 115, 133]. 
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 Given these various observations, the hypothesis of this thesis is that 
p38(MAPK) exerts beneficial effects in [a model of] AD-related pathology, 
specifically by regulating amyloid plaque formation and development. 
 
1.4 Aim of the thesis project 
What the exact role of p-p38(MAPK) plays in the AD brains, and whether p-
p38(MAPK) is harmful or beneficial is a question that needs to be addressed; therefore, 
my project is designed to examine the expression of p-p38(MAPK) in a mouse model of 
AD-related amyloidosis. The mouse model I used is the TgCRND8 mouse that expresses 
a variant of the human APP that contains polymorphisms that have been linked to AD. I 
chose to use immunohistochemistry and immunofluorescence to examine the distribution 
of the p-p38(MAPK) protein in both wildtype and TgCRND8 mouse cortex, and, more 
specifically, its distribution in relation to amyloid plaques. As it is difficult to draw any 
conclusions from the examination of the pathology at a single time point (or age), I chose 
to include mice at different ages; the age-dependent changes allowed me to determine 
more precisely the relation of p-p38(MAPK) to amyloid plaque formation. Rather than 
simply collecting qualitative data, which are also very difficult to interpret, I used 
stereology, which is a statistics-based sampling technique that allows for unbiased and 
accurate estimates of cells (including number, size and shape). Stereology allowed me to 
quantify and measure changes in p-p38(MAPK) distribution as a function of age and 
amyloid plaque deposition. 
The use of specific markers and stains allowed me to identify different plaque 
types as well as the specific cell types that express p-p38(MAPK) in this context. 
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2. MATERIALS AND METHODS 
2.1 Animal model 
The APPSwe/Ind TgCRND8 mouse is a transgenic model of AD-related amyloidosis. 
These mice express a transgene incorporating both the Swedish mutation 
(K670N/M671L) and the Indiana mutation (V717F) in the human APP protein [134]. 
These authors have clearly demonstrated that expression of this transgene results in the 
production of A and the aggregation of A into plaques at a very early age (normally 
around 12-14 weeks). These mice were a gift from Dr. David Westaway at the Centre for 
Research Neurodegenerative Disease (University of Toronto, Toronto, ON, Canada). All 
procedures were performed in accordance with the Canadian Council on Animal Care 
Guidelines and were approved by the University of Saskatchewan Animal Care 
Committee (protocol# 20060070). Genotyping of all animal models was routinely 
performed by Paul Pennington, a member of the Cell Signalling Laboratory. 
 
2.2 Antibodies 
2.2.1 p38(MAPK) antibodies 
        The p38(MAPK) protein was detected with a mouse monoclonal p38(MAPK) 
antibody (#9217) purchased from Cell Signalling Technology (Danvers, MA, USA). 
This antibody detects all of the isoforms of p38(MAPK) and does not cross-react with 
other MAPK kinases. The dilution ratio used for the immunohistochemistry and 
immunofluorescence was 1:100. The p-p38(MAPK) protein was detected using a rabbit 
polyclonal antibody (#9211) purchased from Cell Signalling Technology (Danvers, MA, 
USA). This antibody (used at a dilution of 1:100) recognizes the activated conformation 
of p38(MAPK), i.e. phosphorylated on threonine 180 and tyrosine 182. 
 
2.2.2 Plaque associated antibody 
         The mouse monoclonal anti-APP (6E10) antibody was used for detecting the 
amyloid deposits. This antibody is reactive to amino acid residues 1-16 of Aβ and was 
used at a concentration of 1:1000. This antibody was purchased from Covance 
(Princeton, NJ, USA). 
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2.2.3 Antibodies as cell markers 
The mouse anti-neuronal nuclei (NeuN) monoclonal antibody (MAB337; clone 
A60) is a specific antibody for most neuronal cell types (exceptions include Purkinje 
cells, mitral valve cells and photoreceptor cells). The NeuN antibody was diluted at a 
ratio of 1:1000 and was obtained from Millipore (Billerica, MA, USA) 
Astrocytes were detected using the mouse monoclonal anti-glial fibrillary acidic 
protein (GFAP) (G3893) at a dilution of 1:1000. The antibody was obtained from Sigma-
Aldrich Ltd (St Louis, MO, USA) 
Both of the mouse anti-Macrophage-1 (CD11b/CD18) (Mac-1)/anti-CD11b 
(MCA74G) and mouse anti-ectodermal dysplasia-1 (CD68) (ED-1)/anti-CD68 
(MCA341R) antibodies were used for detecting microglia. The dilution used for these 
two antibodies was 1:1000. Both antibodies were obtained from Serotec (Raleigh, NC, 
USA). 
 All the antibodies mentioned above were diluted in PBS/0.3% Triton X-100 
(PBS-TX). PBS (phosphate buffered saline) is a buffer solution widely used in biological 
research. This water-based salt solution maintains a constant pH and provides a condition 
with almost the same ion concentrations and osmolarity of human body. Triton X-100 is 
a non-ionic surfactant than can increase the permeability of the cell membrane and 
reduce solution surface tension during immunostaining. Making the antibody solution 
with PBS-TX can help to preserve the integrity and condition of the tissue sections, and 
also increase the quality of immunostaining. All primary antibodies were stored at -20°C. 
 
2.3 Methods 
2.3.1 Gelatin-coating slides 
Pre-coating slides with gelatin helps affix tissue to the slides, and reduces the 
chance of a tissue sample being lost during processing. Slides were prepared as follows:  
1) Melvin freed microscope slides were placed in slide racks. 
2) The slides were soaked in fresh gelatin solution for ½ hour and dried overnight in 
at 60°C. 
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3) Repeat step 2. 
4) Slides were stored in slide boxes at 4°C up to one month until use. 
 
Preparation of fresh gelatin solution: 
1) Add 2.5 g gelatin to 300 ml distilled water and heat to dissolve. 
2) Cool to room temperature (RT). 
3) Add chromium potassium sulfate [CrK(SO4)2]. 
4) Bring to volume (500 mL) with distilled water. 
 
2.3.2 Perfusion and brain fixation 
        Mice were treated in accordance with the University Committee on Animal Care 
and Supply/Canadian Council on Animal Care guidelines. The 3-, 6- and 10-month 
TgCRND8 and wildtype mice were sacrificed and perfused by transcardial perfusion. 
The brains were removed and fixed for immunohistochemistry. Perfusion is a means of 
removing blood from the body and brain, which prevents antibodies from reacting non-
specifically with molecules in the blood. Fixation crosslinks proteins in the tissue, 
thereby preventing proteins from being digested by enzymes. It can optimize 
preservation of cellular structures and antigens. In addition, it also prevents post-mortem 
decay and extrinsic damage by bacteria as well as increases the mechanical strength and 
stability of brain tissue. As a result, brains can also be stored for much longer prior to 
use. 
   
1) Mice were anaesthetized by intraperitoneal injection of pentobarbital sodium (50 
mg/kg) and closely monitored to make sure the animals were completely under 
the anesthetic. 
2) Animals were immobilized on the operating table by taping the limbs. The 
thoracic cavity was then opened to expose the heart for transcardial perfusion. 
3) A 10 ml syringe was filled with PBS and the left ventricle of the mouse’s heart 
was cut open to allow for the PBS to drain from the circulatory system once it 
had perfused the brain (and the rest of the body). The heart was held in place with 
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forceps while the syringe was inserted into right atrium and PBS was pushed 
through the heart. 
4) Once perfused, the head was detached and the skull was exposed. The cranial 
cavity was opened and the brain was removed and rinsed in PBS. 
5) The brain was post-fixed in 4% paraformaldehyde (PFA) by immersion in 
approximately 5 ml of the solution for 24 h at 4°C. 
6) The brain was then transferred into 30% sucrose, immersed in the solution for 48 
h at 4°C, and frozen on dry ice. 
7) The brain tissue was stored at -70°C until sectioned coronally. 
 
Preparation of PBS: 
1) Add 15.4 mg sodium hydrogen phosphate (NaHPO4) and 67.3 mg sodium 
phosphate monobasic monohydrate (NaH2PO4.H2O) into 2000 ml distilled water 
to make 2 M Phosphate Buffer (PB). 
2) Add 18 mg sodium chloride and 100 ml 2 M PB in 1900 ml distilled water to 
make PBS. 
 
Preparation of 4% PFA in 0.1M PB: 
1) Mix 20 g PFA powder in 200 ml distilled water. 
2) Heat to 60°C and add 2N NaOH drop-wise until solution is clear. 
3) Bring volume up with distilled water to 250 ml and add 250 ml 0.2 M PB. 
 
Preparation of 30% sucrose solution: 
1) Make 130 mM Na Phosphate by mixing 72.9 ml 1M Na2HPO4 and 27.1 ml 1M 
NaH2PO4. 
2) Dissolve 30 g sucrose in 100 ml of 130 mM Na Phosphate. 
 
2.3.3 Brain sectioning  
1) To avoid the activation of enzymes and to keep the brain in good condition, the 
temperature of the cryostat was kept at -20°C or lower. The fixed brain tissue was 
24 
 
transferred from -70°C to -20°C one day before being sectioned to bring the 
temperature of the tissue to that of the cryostat. 
2) A 24-well plate was filled with PBS and placed on an ice pack.  
3) The brain was taken from -20°C and placed in the cryostat chamber. The brain 
was then affixed to a metal base using tissue mounting medium. To ensure that 
the brain was firmly mounted in the mounting media, the procedure was 
completed on the cryobar set at -61°C. 
4) The metal base was orientated on the specimen bar in a manner that allowed the 
brain to be sectioned coronally. 
5) The section thickness of brain was 30 µm. This thickness was selected to allow 
for a) adequate penetration of the primary antibody into the tissue; and b) 
stereological quantification of the immunohistochemical markers used in the 
study.  
6) The sectioned brain tissue was saved in the 24-well plate following the order of 
well number 1 to 24 in rotations. 
7) The brain sections were transferred to another 24-well plate filled with PBS to 
rinse out any mounting medium still attached to the tissue sections, and then 
stored at 4°C overnight. 
8) The brain sections were transferred in a 24-well plate filled with glycerol buffer 
and stored at 4°C until use. 
 
2.3.4 Immunohistochemistry 
         Immunohistochemistry is based on the principle of the specific binding between 
antibodies and antigens (e.g. proteins) in the cells of the tissue section. All the 
immunohistochemical experiments in this project followed the ‘indirect method’, which 
involves the identification of the target protein by first binding the primary antibody to 
the target protein, and then detecting the antibody-protein complex with an enzyme-
conjugated secondary antibody directed against the primary antibody. The immune 
complex can be visualized by conversion of a substrate (by the enzyme conjugate) to a 
visible product. 
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1) Brain sections were taken from the 4°C glycerol buffer and placed in an 
appropriate container (6-, 12-, or 24-well plate) filled with PBS. 
2) The free-floating sections were washed 3 times in PBS (each wash = 30 min). 
3) Sections were incubated for 30 min in 10 mM sodium citrate buffer at 70°C for 
antigen retrieval and the sections were cooled (RT, 30 min). 
4) Sections were washed 3 times in PBS (each wash = 15 min). 
5) Sections were immersed in 0.2% H2O2 for 30 min to inhibit endogenous 
peroxidase activity following three 15 min washes in PBS.  
6) Sections were incubated (RT, 1.5 h) in 5% normal serum in PBS-TX to block the 
non-specific binding of primary and secondary antibodies. 
7) Sections were then incubated for 72 h at 4°C and 2 h at RT in PBS-TX with the 
primary antibody. 
8) Sections were washed 3 times in PBS (each wash = 30 min). 
9) Sections were blocked with 2.5% normal serum before adding the secondary 
antibody in PBS-TX for 1h. 
10) Sections were incubated with the secondary antibody (RT, 1.5 h) in PBS-TX 
followed by three 20 min PBS washes. 
11) Sections were incubated with the avidin-biotin complex solution (ABC kits) 
(Vector Laboratories, Inc., Burlington, ON, Canada) for 1 h following 3 times 15 
min PBS washes. 
12) Sections were processed by the 3,3′-diaminobenzidine (DAB) staining method for 
15-30 min for colorimetric visualization and then transferred into PBS. 
13) Sections were mounted on gelatin-coated slides and dried overnight. 
14) Mounted sections were immersed in ascending ethanol concentrations for 
dehydration, and then placed in xylene for clearing and dissolving ethanol. 
15) Slides with sections were cover-slipped with Permount Mounting Media (Sigma 
Aldrich Ltd.) and prepared for microscopy. 
 
Preparation of 0.2% H2O2 in PBS: 
1) Add 100 μl H2O2 to 900 μl distilled water to make 30% H2O2. 
2) Add 332.75 μl of 30% H2O2 to 50 ml PBS to make 0.2% H2O2. 
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Preparation of PBS/0.3% Triton X-100 (PBS-TX): 
1) Dilute 5 ml Triton X-100 with PBS (to a volume of 50 ml) to make 10% Triton. 
2) Add 1.5 ml 10% Triton to 48.5 ml of PBS to make 0.3% Triton. 
 
Preparation of DAB staining reagent: 
1) Dissolve 500 mg DAB powder in 190 ml distilled water. 
2) Add 10 ml 2 M PBS and then add 1.8 mg NaCl. 
3) Aliquot the DAB staining reagent into 50 ml falcon tubes (each tube = 10 ml) and 
freeze until use. 
4) To use DAB, thaw the frozen aliquot and then add 40 ml PBS and 50 μl of 30% 
H2O2. 
 
2.3.5 Immunofluorescence 
         Immunofluorescence is based on the same principle as immunohistochemistry. 
However, the secondary antibodies are already labeled with a colorimetric indicator (i.e., 
a fluorochrome). This means that once the primary antibody detects the target protein 
and forms an immune complex with the secondary antibody, the interaction will be 
visualized without any further processing. Antibodies used for immunofluorescence, e.g. 
anti-total p38, anti-p-p38, 6E10, NeuN, GFAP, Mac-1 and ED-1, were described in the 
‘Antibodies’ section above. 
 
Procedure for immunofluorescence: 
1) Brain sections were taken from 4°C glycerol buffer and placed in the appropriate 
plates containing PBS. 
2) Free-floating sections were washed 3 times in PBS for 30 min and left overnight 
at 4°C. 
3) Following 3 washes in PBS (each wash = 20 min, RT), sections were incubated 
for 30 min in 10 mM sodium citrate buffer at 70°C for antigen retrieval. The 
sections were then allowed to cool (RT, 30 min). 
4) Sections were washed 3 times in PBS for 15 min. 
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5) Sections were blocked (1.5 h, RT) in 5% normal serum in PBS-TX. 
6) Sections were then incubated for 72 h at 4°C and 2 h at RT in PBS-TX with two 
primary antibodies (so as to target two different proteins concurrently). 
7) Sections were washed 3 times in PBS for 30 min. 
8) Sections were blocked in 2.5% normal serum in PBS-TX for (RT, 1 h) before 
adding the secondary antibody. 
9) Sections were incubated 1.5 h (RT) with the appropriate two fluorescent 
secondary antibodies raised against the two primary antibodies in PBS-TX (used 
in point 6, above). 
10) Sections were washed 3 times in PBS for 20 min and mounted on gelatin-coated 
slides. 
11) Prolong Gold Fluorescent Mounting Media (Invitrogen #P36930) was added to 
the sections and these were then covered with a coverslip and prepared for 
confocal microscopy.  
 
Fluorescence secondary antibodies include: Alexa Fluor 488 donkey anti-mouse, 488 
donkey anti-rabbit, 594 donkey anti-rabbit, 555 goat anti-mouse, 555 goat anti-rabbit (all 
from Invitrogen). 
 
2.3.6 Staining methods 
         Both of the Thioflavin-S staining and Nissl staining are reported as reliable markers 
of the central core of ‘dense-core’ plaques. Therefore, these two staining methods were 
used in this project to detect the cores. 
 
2.3.6.1 Thioflavin-S staining 
1) Sections were transferred from glycerol buffer to PBS and washed 3 times in  
PBS for 30 min 
2) Sections were mounted on gelatin-coated slides and were allowed to dry. 
3) Slides with sections were placed in the slide racks. 
4) The slide racks were immersed in a glass trough filled with 1% Thioflavin-S for 5 
to 10 min. 
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5) The slides were taken from the Thioflavin-S solution and placed in an empty 
glass trough. The slides were rinsed in running water for 2 min (Running water 
should be added gently along a corner of the trough to avoid sections being 
flushed off of the slides). 
6) Slides were covered in 70% ethanol for 5 min (twice). 
7) Sections were covered with Prolong Gold Fluorescent Mounting Media (as 
above). 
 
1% Thioflavin-S solution:  
10 mg Thioflavin-S powder in 1 ml distilled water. 
 
2.3.6.2 Nissl (Thionin) staining 
1) Sections were transferred from glycerol buffer to PBS and washed 3 times in PBS 
for 30 min each. 
2) Sections were mounted on gelatin-coated slides and allowed to dry before use.  
3) Slides with sections were placed in the slide racks. 
4) The slide racks were immersed in glass trough filled with 0.2% Thionin solution 
for 5 to 10 min. 
5) Slides were rinsed quickly in distilled water. 
6) The slide racks were placed in 50%, 70%, 95% and 100% ethanol for 15 min 
respectively. 
7) Sections were cleared in xylene for 15 min (twice). 
8) Slides were cover-slipped with Permount Mounting Media. 
 
0.2% Thionin solution:  
2 mg Thionin powder in 1 ml distilled water. 
 
2.3.7 Stereological quantitative analysis      
Stereology is a sampling method that can be used to quantify and measure cell 
number, type, size; regional volume; area fraction, etc. in a three-dimensional space. 
Compared with traditional counting methods, stereology is more precise and unbiased. In 
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this project, the number of p-p38(MAPK) immunoreactive (IR) cells in the sensorimotor 
cortex of wildtype and TgCRND8 mice was quantified using StereoInvestigator software 
(at 40X magnification). Sections from the wildtype and TgCRND8 mouse brains were 
processed for p-p38(MAPK) DAB immunohistochemistry. p-p38-IR cells appeared as 
brown (because of the DAB). 
The optimal counting frame size to be used for stereology was determined 
through a preliminary population estimate, which resulted in a 100 m2 counting frame 
distributed in a 150 m2 counting grid (Figure 5). The average section thickness was 14 
m. Therefore, p-p38(MAPK)-IR cells were counted through a depth of 12 m, leaving a 
2 m guard zone at the top of the section. 
 
The StereoInvestigator software complementing a BX-51 fluorescence microscope 
system (Olympus Canada; Markham, ON, Canada) was used as follows: 
1) Sections were placed on the microscope stage and the region of interest (the 
sensorimotor cortex) was identified using the 4X objective.  
2) A ‘live’ image of the brain region was viewed on the computer screen. 
3) Information regarding the number of sections to be counted, the thickness of the 
cut sections, and the section evaluation interval was entered into the software. 
4) A box was drawn to outline the sensorimotor cortex in each brain section.  
5) The size of the counting grid (Figure 5) was entered into the software.  A 
“counting frame” (i.e., a “sampling box”) was placed within each counting grid 
automatically by the software.   
6) The cell numbers were counted in the counting frame under 40X magnification. 
For each counting frame, cells were first counted in the two-dimensional plane at 
the top of a section (Shown as the top picture in Figure 5). When cells touched 
the border of the counting frame, only the cells on the green border were counted, 
whereas cells which touched the red border of the counting frame were not 
counted. Given that the diameter of the p-p38(MAPK) cells is less than the 
thickness of section (shown as the bottom picture in Figure 5), there was more 
than one layer of p-p38(MAPK) cells in a section. Therefore, after the counting of 
the top layer was completed, the counting frame was moved through the Z-axis to 
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the next layer and cells were counted in this layer by the same way. When all 
cells in all layers were counted from the top to bottom of the section, the cell 
counting in this counting frame was finished. However, cells were not counted if 
they came into focus within the 2 m ‘guard zone’ at the top of the tissue. 
7) After all the cells in all the counting frames were counted, the mean cell count per 
sampling box (per unit area) was then calculated. 
 
Amyloid plaques were identified by Thioflavin-S (detects the fibrillar 
conformation of amyloid) and/or 6E10 (the anti-APP/A antibody). It became apparent 
that a clustering of three or more p-p38(MAPK)-IR cells was a reliable marker of Aβ 
plaques, and thus these three or more cells that were in direct contact with a plaque were 
counted as ‘plaque-associated p-p38 (MAPK)-IR cells’. In contrast, p-p38(MAPK)-IR 
cells were counted as ‘parenchymal’ cells if they were distributed throughout the 
parenchyma and were not adjacent to two or more other p-p38(MAPK)-IR cells or to a 
plaque. The density of ‘plaque-associated’ as well as ‘parenchymal’ p-p38(MAPK)-IR 
cells were estimated across all the six layers of the cortex on six sections to bring the 
coefficient of error in sampling variance to <0.05. 
 
2.3.8 Confocal microscopy 
The distribution of p-p38(MAPK)-IR cells around 6E10-positive ‘diffuse’ 
plaques was observed using the 40X air objective and a BX71 Olympus confocal 
microscope (and Fluoview SV500 software). Double-labeled images of the p-
p38(MAPK)-IR cells with different cell markers (e.g. NeuN, GFAP, Mac-1 and ED-1) 
were obtained under the 60X oil immersion lens. Double-immunofluorescence for p-
p38(MAPK) and total p38(MAPK) was captured using the 100X oil immersion lens. The 
main procedure of taking pictures under confocal microscopy was as follows: 
1) The region of interest was selected. 
2) The ‘live view’ image was captured and displayed in the Fluoview software. 
3) The brightness and contrast of the live image were optimized. 
4) The coordinates for the top and bottom of the section were identified using the 
software and set up in the Z-axis. 
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5) The scanning interval through the thickness of section was set up (e.g. if the 
section is 10 μm thick and the interval is set up as 1 μm between each scanning, 
11 layers of the section will be scanned and captured by the software).  
6) Scanning was started under the ‘XYZ’ mode, in which section will be scanned 
from the top to bottom along the Z-axis. 
7) The two transmission channels (from the Ar and He lasers) were captured 
simultaneously and filtered by 8 Kalman low-speed scans. 
 
2.3.9 Statistics 
All statistics were performed using Graphpad Prism (v3.01), unless stated 
otherwise. Significance (set at p<0.05) was assessed by one-way or two-way ANOVA 
with post-hoc analysis based on Bonferroni’s Multiple Comparison Test. The Pearson 
product-moment correlation coefficient was used to measure the strength of the linear 
relationship between factors, e.g. the number of plaque-associated p-p38(MAPK)-IR 
cells and the core size [i.e. absolute core size or core size as a proportion of the size of 
the plaque within which it is located]. The stereological statistical sampling protocol is 
described in the ‘Stereological quantitative analysis’ section above and was performed 
using the StereoInvestigator software (MicroBright-Field, Inc.). Data are represented as 
mean ± SEM, and P-values are provided as summary statistics. 
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3. RESULTS 
3.1 Fibrillar and non-fibrillar Aβ increase with age in the sensorimotor cortex of 
TgCRND8 mice. 
To confirm the TgCRND8 mouse as an aggressive model of AD-related 
amyloidosis, the progression of amyloid plaque deposition in 3-, 6- and 10-month 
TgCRND8 mice was assessed by both 6E10 (anti-APP) immunofluorescence and 
Thioflavin-S staining (Figure 6). A 10-month-old wildtype mouse was included as a 
control. 6E10 immunoreactivity as well as Thioflavin-S-positive plaques were detected in 
young animals (confirming the aggressive nature of the transgene) and appeared to 
increase in an age-dependent manner in the sensorimotor cortex in the TgCRND8 mouse 
sections. Plaques were not detected in the 10-month-old wildtype mouse. Two types of 
plaque, ‘dense-core’ and ‘diffuse’ plaques were observed. In ‘dense-core’ plaques, a solid 
central core showed stronger 6E10 immunoreactivity (IR) than the peripheral part of the 
plaque, which surrounded the central core as a halo (Figure 7). However, the pattern of 
6E10-IR and Thioflavin S staining within ‘diffuse’ plaques was quite distinct from the 
‘dense-core’ plaques. Diffuse plaques were characterized by a punctate 6E10-IR that was 
evenly distributed over the entire plaque, without any distinct 6E10-IR or Thioflavin-S 
staining in the center of the plaque. Merging of Thioflavin-S staining and 6E10-IR from 
the same ‘dense-core’ plaque showed a complete co-localization, confirming the identity 
the ‘dense-core’ plaque. Furthermore, Thioflavin-S selectively stained the ‘dense-core’ 
plaques, providing us with a quick means to distinguish the two different kinds of 
plaques. 
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3.2 Distribution of p-p38(MAPK) immunoreactivity in sensorimotor cortex of 
wildtype and TgCRND8 animals. 
Double-labeled immunofluorescence was performed with anti-p-p38(MAPK) and 
anti-p38(MAPK) [recognizes total p38(MAPK)] in sections from wildtype and 
TgCRND8 animals. As expected, the p-p38(MAPK)-IR cells were also p38(MAPK)-IR 
(Fig 8). Although the p-p38(MAPK)-IR was predominately localized in the nucleus, 
whereas the p38(MAPK)-IR was primarily observed in the cytoplasm, this is expected as 
the activated form of p38(MAPK) does translocate to various subcellular compartments. 
Co-localization of the two signals was evident in the cell’s processes (Figure 8).  
        Brain sections from 3-, 6- and 10 month wildtype and TgCRND8 animals were 
stained by DAB-immunohistochemistry with the anti-p-p38(MAPK) antibody. In both 
the wildtype and TgCRND8 mouse cortex, the same pattern of equidistantly distributed 
p-p38(MAPK)-IR cells were detected throughout the parenchyma of the sensorimotor 
cortex at 3-, 6- and 10-months (Figure 9). In addition, a higher density of p-p38(MAPK)-
IR cells was observed in the vicinity of patches [amyloid plaques?] in TgCRND8 mice. 
In accordance with the results revealed by the 6E10 immunofluorescence and Thioflavin-
S staining (Figure 6), the patches increased with age in TgCRND8 mice and there were 
no ‘patches/plaques’ found in wildtype mice. A section without the primary antibody 
[anti-p-p38(MAPK)] was included as a control and clearly shows a lack of p-p38(MAPK) 
signal. These data (Figure 9) confirmed the specificity of the anti-p-p38(MAPK) antibody 
and suggested that p-p38(MAPK)-IR cells are also associated with amyloid plaques. 
        An association between p-p38(MAPK) and amyloid plaques was suggested, yet it 
was unclear one or both types of plaques identified in Figure 6 were associated with p-
p38(MAPK)-IR. The DAB-immunohistochemistry sections were then stained using 
Thioflavin-S and thionin/Nissl stain (stains nucleic acids (DNA/RNA) and is useful for 
viewing cells). The thionin staining of the central core of the plaque was paralleled by 
staining for Thioflavin-S. Some of the plaques showed neither Thioflavin-S nor thionin 
staining, but did show 6E10-IR. Interestingly, p-p38(MAPK)-IR cells were observed in 
clusters that surrounded both types of plaques. This demonstrated that p-p38(MAPK)-IR 
cells were associated with both ‘dense-core’ and ‘diffuse’ plaques. In addition, several 
vasculature-associated p-p38(MAPK)-IR cells were also detected (Figure 10). 
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Figure 9. The distribution of p-p38(MAPK)-IR cells in sensorimotor cortex of 
wildtype and TgCRND8 mice. DAB-immunohistochemistry was used to examine the 
distribution of p-p38(MAPK) immunoreactivity in sections of 3-, 6- and 10-month 
wildtype and TgCRND8 animals. Parenchymal p-p38(MAPK)-IR cells are observed as 
the black dots that are evenly distributed in the parenchyma of wildtype as well as 
TgCRND8 mice cortex at all ages. Meanwhile, DAB-positive patches (subsequently 
identified as amyloid plaques) increase in an age-dependent manner as does the number 
of p-p38(MAPK)-IR cells in the vicinity of these patches. A section without the primary 
antibody (‘no 1’) is included for comparison. Scale bar, 100 μm. 
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3.3 Quantification of p-p38(MAPK)-IR cells in sensorimotor cortex of  TgCRND8 
mice 
      It was observed that p-p38(MAPK)-IR cells were expressed in the sensorimotor 
cortex of both wildtype and TgCRND8 animals at all three ages. As well, a higher 
density of p-p38(MAPK)-IR cells was observed in the vicinity of amyloid plaques. 
However, the reason for the localization of p-p38(MAPK) to amyloid plaques could not 
be defined until aspects of amyloid plaques and p-p38(MAPK)-IR cells were quantified. 
       The mean number of cells (MCC) per unit volume of p-p38(MAPK)-IR cells in the 
sensorimotor cortex of 3-, 6- and 10-month wildtype and TgCRND8 animals were 
obtained by stereological sampling and compared using two-way ANOVA (Figure 11). 
An increased total MCC was observed in the TgCRND8 mice when compared to age-
matched wildtype animals, indicating that genotype accounted for the increase in total 
MCC. As well, age exerted an effect. This was supported statistically: e.g. changes in the 
total MCC were dependent on both genotype (F1, 12 = 89.8, P < 0.0001) and age (F2, 12 = 
16.97, P = 0.0003). Examining the data for associations with specific cell populations 
(e.g. splitting the ‘total’ MCC into ‘parenchymal’ MCC and ‘plaque-associated’ MCC) 
revealed no change in parenchymal MCC with genotype (F1, 12 = 0.0990, P = 0.7584) and 
a modest change with age (F2, 12 = 5.517, P = 0.02). In contrast, plaque-associated MCC 
showed a significant effect for both genotype (F1, 12 = 184.2, P < 0.0001) and age (F2, 12 = 
36.35, P < 0.0001). The genotype and age-related increases in total MCC was exclusively 
due to the increase in plaque-associated p-p38(MAPK)-IR MCC (Figure 11A).  
      3-, 6- and 10-month TgCRND8 mice were then used to quantify the density of 
plaques in sensorimotor cortex. The number of both cortical ‘dense-core’ and ‘diffuse’ 
plaques was estimated in the same cortical volume. Both plaque types increased with age, 
although the age-dependent increase was more remarkable for the ‘dense-core’ plaques 
(F2, 6 = 44.68, P = 0.0002) than ‘diffuse’ plaques (F2, 6 = 20.85, P = 0.002). In addition, 
the increased density of amyloid plaques, especially the ‘dense-core’ plaque (by virtue of 
greater availability than that of diffuse plaques: Figure 11B), could be the type of plaque 
preferentially targeted by the ‘plaque-associated p-p38(MAPK)-IR’ cells in the 
sensorimotor cortex of TgCRND8 mice. This notion was examined next.  
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Examinations were performed in the 3-, 6- and 10-month TgCRND8 mice. The 
size of individual ‘dense-core’ plaques significantly increased with age (F2, 234 = 12.17, P 
< 0.0001); however, the size of individual ‘diffuse’ plaques was not significantly 
different across age groups (F2, 91 = 1.561, P = 0.2155) (Figure 12A). The number of p-
p38(MAPK)-IR cells per ‘diffuse’ plaque also remained unchanged with age (F2,91 = 
0.6351, P = 0.5322). Interestingly, compared with the 3-month-old TgCRND8 mice, the 
number of p-p38(MAPK)-IR cells located in individual ‘dense-core’ plaques increased in 
the 6-month-old TgCRND8 mice (F2,234 = 9.513, P < 0.0001). However, the increase was 
no longer significant or even showed a slight decrease in the 10-month-old TgCRND8 
mice (Figure 12B). The mean number of p-p38(MAPK)-IR cells per plaque area and per 
core area were quantified, and the number of ‘dense-core’ plaque-associated p-
p38(MAPK)-IR cells decreased as a function of the plaque size (F2,234 = 10.92, P < 
0.0001) (Figure 12C) and core size with age (F2,234 = 70.16, P < 0.0001) (Figure 12D). In 
addition to the quantification of the mean number of ‘dense-core’ plaque-associated p-
p38(MAPK)-IR cells, the number of ‘diffuse’ plaque-associated p-p38(MAPK)-IR cells 
was not significantly changed (F2,91 = 0.7643, P = 0.4686) (Figure 12C). Furthermore, the 
average size of Thioflavin-S positive cores increasing with age was observed when the 
mean number of p-p38(MAPK)-IR cells per core area was examined (F2,234 = 19.52, P < 
0.0001) (Figure 12D). These data suggest that the growth of ‘dense-core’ plaques will 
slow down with age, but the fibrillar conformation of the Aβ, Thioflavin-S positive core 
itself will continue to develop with age; and that the core development is inversely 
correlated with the number of plaque-associated p-p-38(MAPK)-IR cells. 
The graphs and explanations for all the quantification and analyses, especially for 
the ‘dense-core’ plaque-associated p-p38(MAPK)-IR cells, could be better understood 
with an example of the analyses. One such example is given on the next page. 
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Table 1. The example of stereological quantification and analyses 
 
○1 : The ‘plaque’ in the table represents ‘dense-core’ plaque. 
○2 : The ‘cell’ in the table represents ‘dense-core’ plaque-associated p-p38(MAPK)-IR 
cells. 
 
In this table, the number of ‘dense-core’ plaque-associated p-p38(MAPK)-IR cells 
per volume of cortex, the number of ‘dense-core’ plaques per volume of cortex, the 
‘dense-core’ plaque size and the Thioflavin-S positive core size all increase with age. 
This is demonstrated in Figures 11A, 11B, 12A and 12D, respectively. The number of 
‘dense-core’ plaque-associated p-p38(MAPK)-IR cells per plaque increases in 6-month-
old TgCRND8 mice and then shows a decrease in 10-month-old mice, matching with 
Figure 12B. Interestingly, although all these are increased over the 3-month samples, the 
calculation of the number of ‘dense-core’ plaque-associated p-p38(MAPK)-IR cells per 
plaque area and per core area are decreased, supporting the graphs/data in Figures 12C 
and 12D.  
 
3.4 The correlation between p-p38(MAPK)-IR cell density differs with absolute and 
proportional core size 
The number of p-p38(MAPK)-IR cells was clearly associated with core 
development in ‘dense-core’ plaques. Therefore, it was necessary to determine whether 
there was an actual correlation (using Pearson’s correlation) between the mean number of 
p-p-38(MAPK)-IR cells per ‘dense-core’ plaque and core size. The proportional core size 
Age of 
TgCRND8 
mice 
Plaque○1  
number 
/cortex 
volume 
Cell ○2  
number 
/plaque 
Cell 
number 
/cortex 
volume 
Plaque 
size 
(μm2) 
Cell 
number 
/plaque 
area 
Core 
size 
(μm2) 
Cell 
number
/ core 
area 
3-month 1 2 2 1 2 1 2 
6-month 2 4 8 3 1.33 2.25 1.78 
10-month 5 3 15 3.25 0.92 3 1 
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Figure 12. p-p38(MAPK)-IR cells are associated primarily with dense-core plaques. 
Sections from 3-, 6- and 10-month TgCRND8 mice were used for the quantification. (A) 
The average size of ‘dense-core’ plaques increases with age, whereas the size of ‘diffuse’ 
plaques modestly changes with age. (B) The mean number of p-p38(MAPK)-IR cells per 
‘dense-core’ plaque increases in 6- vs. 3-month-old mice, but this effect of age is no 
longer significant in the 10-month-old mice. The number of p-p38(MAPK)-IR cells per 
‘diffuse’ plaque basically remains unchanged with age. (C) The number of p-
p38(MAPK)-IR cells associated with ‘dense-core’ plaques decreases as a function of the 
plaque size with age, but there is no effect associated with ‘diffuse’ plaques. (D) The 
mean number of p-p38(MAPK)-IR cells per volume of core decreases (black bars), while 
the size of dense cores increases with age (grey bars). n = 3-4 animals; *P < 0.05; **P < 
0.01; ***P (###P) < 0.001; n.s., not significant. 
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was defined as the percentage of the total ‘dense-core’ plaque area that is occupied by the 
Thioflavin-S positive core. The absolute core size and absolute ‘dense-core’ plaque size 
were measured in the sensorimotor cortex of all the three ages of TgCRND8 mice, and 
the proportional core size was then calculated using the values of absolute core size and 
absolute plaque size. The linear relation between the mean number of p-p38(MAPK)-IR 
cells and absolute core size revealed a positive correlation between these two parameters, 
with the strength of the correlation increasing with age [the age of the animal increases 
from panels A to B to C] (Figure 13). Conversely, a negative correlation between the 
mean number of p-p38(MAPK)-IR cells and proportional core size was observed, but the 
correlation was lost as a function of age [the age of the animal increases from panels D to 
E to F]. Statistical summaries are included in the actual figure. 
 
3.5 The core of ‘dense-core’ plaque expands along the aspect that is devoid of p-
p38(MAPK)-IR cells 
     It was initially observed that DAB-immunohistochemistry could stain patches that 
were subsequently identified as plaques (Figure 9) and that thionin staining could identify 
Thioflavin-S-positive deposits (Figure 10). Using these basic principles, brain sections 
from TgCRND8 mice that had been triple-labeled with Thioflavin-S, thionin and DAB/p-
p38(MAPK) were examined in more detail. The p-p38(MAPK) cells surrounding the 
outside of ‘dense-core’ plaques formed a radial pattern of distribution (Figure 14). As 
expected, the size of Thioflavin-S and thionin staining positive cores tended to increase in 
parallel, while ‘dense-core’ plaques tended to be the predominant form of plaque 
associated with p-p38(MAPK)-IR cells (Figure 14A-D). These changes also correlated 
with the mean number of p-p38(MAPK)-IR cells and the absolute core size. Interestingly, 
the mean number of p-p38(MAPK)-IR cells and the proportional core size was negatively 
correlated, e.g. the number of p-p38(MAPK)-IR cells decreased when the Thioflavin-S- 
and thionin-positive core occupied a higher percentage area of the absolute plaque area.  
However, an additional and very exciting observation was made. Indeed, in 
Figure 12C (above), the mean number of p-p38(MAPK)-IR cells decreased as a function 
of plaque area (an effect that was iterated in the correlation data presented in Figure 13).   
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Figure 13. The correlation between the mean number of p-p38(MAPK)-IR cells with 
absolute core size and proportional core size. 3-, 6- and 10-month TgCND8 mice were 
used. The data depicted in panels A/D, B/E, C/F were obtained from 3-, 6-, 10-month-old 
TgCRND8 mice, respectively. (A-C) The mean number of p-p38(MAPK)-IR cells is 
positively correlated with absolute core size and the correlation enhances with age. (D-F) 
The number of p-p38(MAPK)-IR cells is inversely related to the size of the core as a 
function of the size of the overall plaque and the correlation is lost with age. n = 3-4 
animals. Statistical summaries are included in the individual panels with ‘r’: correlation 
coefficient; P: is the probability value (e.g. significant if ≤0.05); R2: is the square of the 
‘r’ value and helps with the interpretation of the data. For example, in panel C, an R2 
value of 0.3206 means that 32% of the variance in the number of p-p38(MAPK)-IR cells 
can be explained by variation in in the size of the mean core area. 
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In keeping with this, Figure 14C/C′, 14D/D′ clearly suggest that p-p38(MAPK)-IR cells 
may restrict the core maturation and development. Indeed, these images reveal that if a  
core within a plaque is surrounded with the radially distributed p-p38(MAPK)-IR cells, 
the extension of the core is restricted more or less by the cells (Figure 14A/A′, B/B′). 
However, if p-p38(MAPK)-IR cells were no longer present around a plaque, the core 
within this plaque tended to expand outward along the aspect of the plaque that was now 
devoid of p-p38(MAPK)-IR cells. Moreover, in superficial parts of the sensorimotor 
cortex where there are very few, if any, p-p38(MAPK-IR cells (Figure 15A and 15A′), 
what were initially identified as thionin-positive deposits (reminiscent of amyloid 
deposits), were subsequently identified, using Thioflavin-S staining, to be uncontrolled 
growing and amorphic ‘dense-core’ plaques. These kinds of ‘dense-core’ plaques were 
devoid of p-p38(MAPK)-IR cells, which strongly suggested that the p-p38(MAPK)-IR 
cells were not necessarily causing the recruitment of Aβ into the plaques. Given that the 
amyloid core expanded along the aspect that was devoid of p-p38(MAPK)-IR cells, and 
that fibrillar Aβ aggregated to plaques in the absence of plaque-associated p-
p38(MAPK)-IR cells, these observations strongly supported the potential that p-
p38(MAPK)-IR cells could be playing a greater role in restricting the maturation of 
Thioflavin-S-positive core than in promoting the growth of ‘dense-core’ plaques. 
 
3.6 Identification of the phenotype of p-p38(MAPK)-IR cells via using double 
immunofluorescence 
      The literature shows that amyloid plaques are associated with the activation and 
proliferation of microglia and astrocytes [127, 128]. As well, p-p38(MAPK)-IR has been 
observed in the activated microglia, astrocytes and neurons that surround senile plaques 
in the hippocampus of TgCRND8 mice [118]. Therefore, it was important to identify the 
phenotype of p-p38(MAPK)-IR cells that localized to amyloid plaques in the 
sensorimotor cortex of TgCRND8 mice. Not only would this benefit the current project, 
but it would also assist in our understanding of the role of p-p38(MAPK) in AD-related 
pathology. To determine the phenotype of p-p38(MAPK)-IR cells, double 
immunofluorescence with the anti-p-p38(MAPK) antibody and several cell markers were  
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Figure 14. The loss of p-p38(MAPK)-IR cells around a ‘dense-core’ plaque coincides 
with the expansion of Thioflavin-S-positive core. Sections from 3- and 10-month 
TgCRND8 mice were triple labeled by thioflavin-S staining, thionin/Nissl staining and 
DAB-immunohistochemistry with the p-p38(MAPK) antibody. Panels A/A′ and B/B′ 
represent fields within cortical sections from 3-month mice whereas panels C/C′ and D/D′ 
represent fields within cortical sections from 10-month mice. ‘Dense-core’ plaques are 
visualized by both Thioflavin-S (green) and thionin (purple) staining. DAB-
immunohistochemistry (brown) clearly shows the distribution of p-p38(MAPK)-IR cells. 
The loss of p-p38(MAPK)-IR cells in the vicinity of plaques allows the Thioflavin-S-
positive cores to grow out uncontrollably along the aspect devoid of p-p38(MAPK)-IR 
cells (arrows). Asterisk indicates a ‘restricted’ core within a ‘dense-core’ plaque 
surrounded by radially distributed p-p38(MAPK) cells. Scale bars, 20 m. 
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visualized under confocal microscopy. The cell marker antibodies included NeuN 
(neurons), GFAP (astrocytes), ED-1 and Mac-1 (both of ED-1 and Mac-1 detect 
microglia, but the two antibodies selectively recognize different types of microglia or 
microglia in different stages). p-p38(MAPK)-IR was rarely detected in GFAP-positive 
astrocytes and occasionally observed in NeuN-positive neurons (Figure 16). Although 
there was evidence of some p-p38(MAPK) expressing in the ED-1-positive microglia, the 
majority of p-p38(MAPK) were detected in the Mac-1-positive microglia. In addition, the 
Mac-1-positive, p-p38(MAPK)-IR cells were present in parenchyma of both wildtype and 
TgCRND8 mice, and were clearly detetcted around the 6E10-positive plaques (Figure 
16). The p-p38(MAPK)-IR signal was observed in both cytoplasm and nucleus in cells, 
whereas (as expected) Mac-1 predominately labeled the plasma membrane. These data 
confirmed that p38(MAPK) can be constitutively phosphorylated in parenchymal 
microglia in both wildtype or TgCRND8 mouse cortex, and a higher intensity of p-
p38(MAPK)-IR, Mac-1-positive microglia were observed in the vicinity of amyloid 
plaques in the sensorimotor cortex of TgCRND8 mice (Figure 16, 17).  
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3.7 The association between p-p38(MAPK)-IR cells and amyloid plaques in the 
sensorimotor cortex 
      Based on the previous data, although p-p38(MAPK) can be phosphorylated in the 
parenchyma of cortex, a higher intensity of p-p38(MAPK)-IR cells were observed in the 
vicinity of amyloid plaques. The quantification and analyses of the parameters of p-
p38(MAPK)-IR cells and amyloid plaques revealed that the number of p-p38(MAPK)-IR 
cells changed with plaque size and core size. Therefore, as a logical conclusion to this 
project, sections from 6- and 10-month TgCRND8 mice were chosen for double-labeling 
with anti-p-p38(MAPK) and 6E10 (anti-APP) antibodies. The association of p-
p38(MAPK)-IR cells and 6E10-positive amyloid plaques was then examined using 
immunofluorescence. Under the 60X objective, the localization of p-p38(MAPK)-IR 
cells to 6E10-positive amyloid plaques was observed. Most of the p-p38(MAPK)-IR cells 
surrounded the periphery of the plaque, yet some of the processes of these p-
p38(MAPK)-IR cells extended through the outer part of the 6E10-positive plaque and 
ended within the Thioflavin-S-positive core area (Figure 18). In addition, the areas 
immediately peripheral to the plaque that were occupied by p-p38(MAPK)-IR cells were 
devoid of 6E10 signal. These data provided evidence to suggest that these Mac-1/p-
p38(MAPK)-IR cells are not simply ‘resting’ when they are in the vicinity of an amyloid 
plaques, but that they must, in fact, be influencing certain aspects of amyloid load 
(deposition/removal) (Figure 18). This notion was further supported by images taken at 
higher magnification (i.e. 100X objective) (Figure 19). The p-p38(MAPK)-IR microglia 
were scanned from bottom to top (along the Z-axis) at 1 m intervals and a series of 
images was obtained representing serial sections of the p-p38(MAPK)-IR microglia. In 
these images, the 6E10 signal was detected in the p-p38(MAPK)-IR microglia, 
suggesting that the A from the amyloid plaques was being taken into the p-p38(MAPK)-
IR microglia (Figure 19). Note that these experiments do not indicate at this point 
whether this A is simply sequestered or if it is subsequently degraded. 
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4. DISCUSSION 
      
 In this project, I chose to examine the sensorimotor cortex of wildtype and TgCRND8 
mice because disruptions in the function of this structure have recently been associated 
with cognitive impairment during the progression of AD [135, 136]. For example, Frisoni 
et al (2009) reported a progressive grey matter loss of 7-9% and 10-11% in the 
sensorimotor cortex in mild and moderate AD, respectively. The amyloid plaques formed 
during AD are thought to provoke inflammatory responses which are detrimental to the 
surrounding brain tissue. The recruitment of microglia and astrocytes is a key component 
of the inflammatory response. Since increased numbers of microglia and astrocytes are 
observed surrounding amyloid plaques in AD, the increased p38(MAPK) signaling 
detected in these microglia and astrocytes is believed to contribute to both the 
development of the plaques and the disruption of the surrounding parenchymal tissue 
[115, 137, 138]. This notion of a detrimental role for p38(MAPK) is further supported by 
the finding that p38(MAPK) activity is associated with inflammatory signals and 
apoptosis [114, 128, 139, 140]. Reports have suggested that p-p38(MAPK) is primarily 
involved in proinflammatory responses, although it can also regulate the biosynthesis and 
expression of the inflammatory cytokines [69, 141]. On the other hand, others believe 
that the recruitment of microglia to the vicinity of amyloid plaques could be beneficial in 
AD by reducing the A burden and retarding the plaque development [118, 142, 143]. 
While the initial examinations confirmed the presence of p-p38(MAPK)-IR cells in the 
sensorimotor cortex of wildtype and TgCRND8 mice and subsequently identified these 
cells as [predominantly] microglia, it was still unclear whether these p-p38(MAPK)-IR 
microglia were exerting harmful or beneficial effects with regard to the amyloid plaque. 
Therefore, quantification of the data over a span of ages was used to help understand the 
changes, if any, in distribution, localization and concentration of these cells with respect 
to the amyloid plaques. 
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4.1 The presence of p-p38(MAPK)-IR microglia throughout the parenchyma of 
cortex in both wildtype and TgCRND8 mice suggests a non-pathological role for 
these cells.   
      p-p38(MAPK)-IR microglia were detected across the parenchyma of the sensorimotor 
cortex in 3-, 6- and 10-month wildtype and TgCRND8 mice using DAB-
immunohistochemistry (Figure 9). Parenchymal p-p38(MAPK)-IR microglia had already 
been demonstrated in cortex and hippocampus of these mice. In those published studies, 
there were more p-p38(MAPK)-IR cells as well as a greater intensity of the p-
p38(MAPK) signal in TgCRND8 than in wildtype mice [115, 118]. In the current project, 
an apparently evenly distributed pattern of p-p38(MAPK)-IR microglia in cortical 
parenchyma was observed and the presence of parenchymal p-p38(MAPK)-IR cells was 
confirmed stereologically in both wildtype and TgCRND8 mice (i.e. independent of 
genotype) (Figure 11). Moreover, stereological sampling revealed that the number and 
density of these parenchymal p-p38(MAPK)-IR microglia also remained unaffected as a 
function of age in wildtype mice (Figure 11A). This evidence suggests that p38(MAPK) 
can be constitutively phosphorylated in microglia across the cortical mantle and that the 
density of these activated p38(MAPK)-IR microglia is not affected by either genotype or 
age. It is interesting that the density of parenchymal p-p38(MAPK)-IR microglia was 
unaffected by either the presence or density of amyloid plaques or by the localization of a 
significant number of p-p38(MAPK)-IR microglia to the vicinity of amyloid plaques. 
Even in 10-month-old TgCRND8 mice, the parenchymal p-p38(MAPK)-IR microglia 
maintained the same pattern of distribution and same level of expression, although the 
number of amyloid plaques and plaque-associated p-p38(MAPK)-IR microglia was 
greatly increased. Therefore, in comparison to the plaque-associated p-p38(MAPK)-IR 
cells, the parenchymal pool of p-p38(MAPK)-IR microglia can be considered as 
‘resting’, with little or no apparent direct influence on the development of amyloid 
plaques [144, 145]. It is assumed that the plaque-associated p-p38(MAPK)-IR microglia 
originate from this parenchymal pool, but this was not confirmed during the course of the 
present series of experiments. In fact, the literature does indicate that bone marrow-
derived microglia have different inherent properties than the ‘resident’ microglia in the 
brain and that these bone marrow-derived microglia can participate in the response to 
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amyloid deposition [146]. When the bone marrow-derived microglia are diminished in an 
animal model of AD-related pathology, the number of plaque-associated microglia is 
decreased and the development of dense-core plaques is accelerated [142, 147]. The 
current observations support parenchymal p-p38(MAPK)-IR microglia as being ‘resting’ 
and of playing a non-pathological role, perhaps contributing simply to the homeostatic 
maintenance of the brain. It is unclear at this time whether parenchymal p-p38(MAPK)-
IR microglia from other sources are being recruited in response to the development of the 
amyloid plaques in the TgCRND8 mouse model of AD-related pathology. 
 
4.2 The density of plaque-associated p-p38(MAPK)-IR microglia is inversely related 
to the size of Thioflavin-S-positive cores. 
      The plaque-associated p-p38(MAPK)-IR microglia were detected in the vicinity of 
both dense-core and diffuse plaques (Figure 10), but stereological sampling indicated that 
the number of p-p38(MAPK)-IR microglia more closely related with the dense-core 
plaques. The density of plaque-associated p-p38(MAPK)-IR microglia increased in the 
cortex with genotype and age in parallel with the increase in the number and size of 
dense-core plaques in the same area (Figure 11A, 11B and 12A). The presence of dense-
core plaques suggests that the A in this area is aggregating and undergoing a transition 
to the fibrillar conformation. The presence of these plaques is often associated with 
inflammatory pathology that could activate the p38(MAPK) signaling in microglia and 
recruit these cells to the general vicinity of the plaques. As a result, it could be assumed 
that an increase in the number of amyloid plaques could account for the higher density of 
p-p38(MAPK)-IR microglia localized to the vicinity of these plaques in the sensorimotor 
cortex. However, when I focused on the individual dense-core plaques, the number of p-
p38(MAPK)-IR microglia per dense-core plaque showed a significant increase in 6-
month-old TgCRND8 mice, whereas the number stabilized or even decreased slightly in 
the 10-month-old TgCRND8 mouse cortex (Figure 12B). Although the number of both 
plaque-associated p-p38(MAPK)-IR microglia and dense-core plaques increased with age 
in the cortex, differences of the increasing rate were revealed in the different periods 
(Figure 11A and 11 B). The increase in density of the dense-core plaques between the 6-
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month and 10-month TgCRND8 cortices paralleled a decline in plaque-associated p-
p38(MAPK)-IR microglia and was more significant than the increase in density dense-
core plaques from the 3-month to the 6-month cortices. Therefore, the p-p38(MAPK)-IR 
microglia were apparently involved in something different in TgCRND8 mice between 3- 
and 6-months of age and 6- and 10-months of age. Stereology subsequently revealed that 
the number of p-p38(MAPK)-IR microglia localized to an individual dense-core plaque 
dense-core plaque tended to correlate with the size of the individual plaque, but that the 
actual size of the dense core of a plaque tended to increase in those plaques with fewer 
associated p-p38(MAPK)-IR microglia (Figure 13). So as to better understand what could 
be transpiring in these mice, the size of individual dense cores was expressed as 
‘absolute’ (actual size) and ‘proportional’ (in relation to the size of the surrounding 
plaque), and the correlation of the density of p-p38(MAPK)-IR microglia with the two 
kinds of core size was evaluated. The larger dense-core plaques associated with a lower 
density of plaque-associated p-p38(MAPK)-IR microglia in the older transgenic mice, 
which indicated the development (number and size) of dense-core plaques was inversely 
related with the density of p-p38(MAPK)-IR microglia. This finding is consistent with a 
previous report that demonstrated that the induction of plaque-associated cells restricts 
the development of dense-core plaques [148]. In the current study, the Thioflavin-S-
positive core expended along the aspects that were devoid of p-p38(MAPK)-IR microglia 
and amorphic dense-core plaques without radially distributed p-p38(MAPK)-IR 
microglia were detected in the superficial layers of cortex (Figure 14C, D and E). Thus, 
p-p38(MAPK)-IR microglia appear to play a role in restricting the maturation and growth 
of the cores, rather than on the aggregation and development of the amyloid deposit itself. 
While these observation were quite evident in 10-month TgCRND8 mice, it should be 
noted that there were still a number of large plaques (with smaller cores) that were ringed 
by a high number of p-p38(MAPK)-IR microglia. Therefore, not all plaques responded in 
a similar manner [perhaps due to the cortical layer within which they resided and the 
local microenvironment or perhaps due to differences in the type and/or function of the 
local cell population] and not all p-p38(MAPK)-IR cells were ‘removed’ (re-localized 
away from the plaque or simply inactivated) simultaneously. The reason for this remains 
unclear. 
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4.3 p-p38(MAPK)-IR microglia may facilitate the phagocytosis and clearance of A 
deposits 
      The radial distribution of plaque-associated p-p38(MAPK)-IR microglia around 
dense-core plaques included cells whose processes extended into the Thioflavin-S-
positive core area. Besides, when we detected some plaque-associated p-p38(MAPK)-IR 
microglia located at the penumbra (non-fibrillar area) of dense-core plaques, the 
immediate areas adjacent to the p-p38(MAPK)-IR microglia were often devoid of 
6E10/A immunoreactivity (Figure 18). This observation suggested that p-p38(MAPK)-
IR microglia could be helping to clear A. A series of confocal microscopic images 
revealed that the 6E10 (e.g. anti-APP/A) signal could be detected within the margins of 
the p-p38(MAPK-IR microglia (Figure 19), thus strongly supporting the uptake of A 
into p-p38(MAPK)-IR microglia, presumably via a phagocytotic process. This 
corroborated a previous report of p-p38(MAPK)-IR microglia clearing A deposits and 
potentially even denaturing and removing the aggregated/fibrillar form of A [149]. 
 
4.4 The origins of parenchymal and plaque-associated p-p38(MAPK)-IR microglia 
When the number of plaque-associated p-p38(MAPK)-IR microglia increased 
with age and genotype, there was not a corresponding decrease in the parenchymal pool 
of p-p38(MAPK)-IR microglia. Three possibilities could explain this observation. First, 
the parenchymal p-p38(MAPK)-IR microglia were recruited to the vicinity of the 
amyloid plaques and then a new population of parenchymal p-p38(MAPK)-IR microglia 
was activated. Second, the increased number of plaque-associated p-p38(MAPK)-IR cells 
were derived from other sources, such as blood vessels and bone marrow. Lastly, the new 
population of plaque-associated p-p38(MAPK)-IR microglia were derived from local 
mitosis. Given that the resting form of parenchymal p-p38(MAPK)-IR microglia did not 
changes with age or genotype, and that the overall distribution of these cells was not 
disturbed by the presence of the amyloid plaque or plaque-associated p-p38(MAPK)-IR 
microglia, this would suggest that the increased number of plaque-associated p-
p38(MAPK)-IR microglia were probably not originating from the parenchymal pool of p-
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p38(MAPK)-IR microglia. However, previous studies have revealed that 5-bromo-2′-
deoxyuridine (BrdU)-positive microglia could be detected in the vicinity of dense-core 
plaque and as such the local mitosis of p-p38(MAPK)-IR microglia could contribute to 
the increased number of plaque-associated p-p38(MAPK)-IR microglia [150]. Finally, 
several p-p38(MAPK)-IR microglia were observed within the blood vessels in the 
sensorimotor cortex (Figure 10). This observation corroborates several other reports and 
indicates the peripheral vasculature can be an origin of the population of plaque-
associated p-p38(MAPK)-IR microglia [137, 142]. 
 
 
5. FUTURE WORK 
Our laboratory recently observed that p-p38(MAPK) could affect the function of a 
mitochondrial enzyme, monoamine oxidase-A (MAO-A) [116]. Interestingly, MAO-A 
generates hydrogen peroxide as a reaction by-product and because of its potential for 
inducing oxidative stress, MAO-A has been forwarded as a candidate for increasing the 
vulnerability of cells during the progression of AD [151-153]. With this in mind, I used 
immunofluorescence to examine the distribution of MAO-A using two different 
antibodies (H-70 and T-19) in the sensorimotor cortex of wildtype and TgRND8 mice, 
and co-labeled with p-p38(MAPK), Mac-1 or NeuN antibodies in the same sections. I 
was not able to conclusively identify Mac-1-positive cells that were positive for both p-
p38(MAPK) and MAO-A. As such, my initial observations do not support the co-
expression of these two proteins in plaque-associated, Mac-1-positive cells (Figure 20). 
However, MAO-A (Figure 20) could be detected in neurons (NeuN-positive cells). Given 
that I had previously detected p-p38(MAPK) in NeuN-positive cells (Figure 17), this 
supports the possibility that a population of p-p38(MAPK)-IR neurons could be 
influenced by the local activity of MAO-A and could help to link these two proteins, i.e. 
p-p38(MAPK) and MAO-A, in the context of AD-related pathology. As such, I suggest 
that the roles of p-p38(MAPK) and MAO-A, and the exciting possibility that these two 
proteins could be interacting in these neurons, should be examined further in AD-related 
mouse models, including the TgCRND8 mouse. 
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